Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Brands
63,7
%
| 9 890 | 60,8 % | 9 801 | 63,7 % | -0,90% |
Generics
36,3
%
| 5 015 | 30,8 % | 5 588 | 36,3 % | +11,42% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Developed Markets
37,0
%
| 5 844 | 35,9 % | 5 700 | 37,0 % | -2,46% |
United States
23,1
%
| 3 947 | 24,3 % | 3 552 | 23,1 % | -10,00% |
Emerging Markets
16,6
%
| 2 637 | 16,2 % | 2 552 | 16,6 % | -3,24% |
China
12,3
%
| 1 951 | 12,0 % | 1 889 | 12,3 % | -3,19% |
Japan, Australia and New Zealand
9,3
%
| 1 634 | 10,0 % | 1 425 | 9,3 % | -12,81% |
Greater China
1,8
%
| 250 | 1,5 % | 271 | 1,8 % | +8,60% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Scott Smith
CEO | Chief Executive Officer | 61 | 29/12/22 |
Abhijit Barve
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | 16/11/20 | |
David Bayles
CMP | Compliance Officer | - | 16/11/20 |
Chief Tech/Sci/R&D Officer | - | - | |
Philippe Martin
CTO | Chief Tech/Sci/R&D Officer | - | 15/12 |
Rajiv Malik
BRD | Director/Board Member | 63 | 16/11/20 |
Investor Relations Contact | - | 01/11/20 | |
Bill Szablewski
IRO | Public Communications Contact | - | 16/11/20 |
Burt Park
LAW | General Counsel | - | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Melina Higgins
CHM | Chairman | 56 | 16/11/20 |
Mark Parrish
BRD | Director/Board Member | 68 | 16/11/20 |
Harry Korman
BRD | Director/Board Member | 66 | 16/11/20 |
James Kilts
BRD | Director/Board Member | 76 | 16/11/20 |
Elisha Finney
BRD | Director/Board Member | 62 | 29/12/22 |
Robert Coury
BRD | Director/Board Member | 63 | 16/11/20 |
Rajiv Malik
BRD | Director/Board Member | 63 | 16/11/20 |
Scott Smith
CEO | Chief Executive Officer | 61 | 29/12/22 |
JoEllen Dillon
BRD | Director/Board Member | 60 | 16/11/20 |
Richard Mark
BRD | Director/Board Member | 70 | 16/11/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 1 231 159 482 | 1 186 316 314 ( 96,36 %) | 40 483 663 ( 3,288 %) | 96,36 % |
Coordinate società
Viatris, Inc.
Robert J. Coury Global Center 1000 Mylan Boulevard
15317, Canonsburg
+724 514 1800
http://www.viatris.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Utah Acquisition Sub, Inc.
Utah Acquisition Sub, Inc. Pharmaceuticals: MajorHealth Technology Part of Viatris, Inc., Utah Acquisition Sub, Inc. is an American pharmaceutical company. The company is located in the US. |
Pharmaceuticals: Major
|
Biosimilars Newco Ltd.
Biosimilars Newco Ltd. Chemicals: SpecialtyProcess Industries Part of Viatris, Inc., Biosimilars Newco Ltd. is a British company that manufactures organic chemicals. The company is located in the UK. |
Chemicals: Specialty
|
Settore
Vendite per attività
Vendite per regione
Variaz. 1 gen. | Capi. | |
---|---|---|
+61,53% | 856 Mrd | |
+38,95% | 631 Mrd | |
-3,66% | 359 Mrd | |
+15,06% | 325 Mrd | |
+9,18% | 297 Mrd | |
+5,89% | 234 Mrd | |
+16,53% | 226 Mrd | |
+15,67% | 177 Mrd | |
+2,47% | 165 Mrd |